Skip to content

Study · Animal study (in vivo) · mouse · 2020

20 results

Abaloparatide at the Same Dose Has the Same Effects on Bone as PTH (1-34) in Mice.

Le Henaff C, Ricarte F, Finnie B, He Z, Johnson J, Warshaw J, Kolupaeva V, Partridge NC

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research27 Dec 2019Cited by 35 (Europe PMC)

PMID31793033 (opens in a new tab)PMCIDPMC7145759 (opens in a new tab)DOI10.1002/jbmr.3930 (opens in a new tab)PepBankPUB-31793033
Source linkPubMedAsk about this study
Jump to 20 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

20 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, abaloparatide produced similar BMD increases at all measured sites compared with PTH (1-34).

    In plain wordsIn mice, abaloparatide increased bone density similarly to PTH (1-34).

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBMD at all sites
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Our results showed that, compared with PTH (1-34), abaloparatide resulted in a similar increase in BMD at all sites, whereas no changes were found with PTHrP (1-36).
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, PTH (1-34) produced similar BMD increases at all measured sites compared with abaloparatide.

    In plain wordsIn mice, PTH (1-34) increased bone density similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBMD at all sites
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Our results showed that, compared with PTH (1-34), abaloparatide resulted in a similar increase in BMD at all sites, whereas no changes were found with PTHrP (1-36).
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, abaloparatide increased bone volume similarly to PTH (1-34).

    In plain wordsIn mice, abaloparatide increased bone volume similarly to PTH (1-34).

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBone volume
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    With both PTH (1-34) and abaloparatide, μCT and histomorphometry analyses revealed similar increases in bone volume associated with an increased trabecular thickness, in bone formation rate as shown by P1NP serum level and in vivo double labeling, and in bone resorption as shown by CTX levels and osteoclast number.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, PTH (1-34) increased bone volume similarly to abaloparatide.

    In plain wordsIn mice, PTH (1-34) increased bone volume similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBone volume
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    With both PTH (1-34) and abaloparatide, μCT and histomorphometry analyses revealed similar increases in bone volume associated with an increased trabecular thickness, in bone formation rate as shown by P1NP serum level and in vivo double labeling, and in bone resorption as shown by CTX levels and osteoclast number.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, abaloparatide increased trabecular thickness similarly to PTH (1-34).

    In plain wordsIn mice, abaloparatide increased trabecular thickness similarly to PTH (1-34).

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeTrabecular thickness
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    With both PTH (1-34) and abaloparatide, μCT and histomorphometry analyses revealed similar increases in bone volume associated with an increased trabecular thickness, in bone formation rate as shown by P1NP serum level and in vivo double labeling, and in bone resorption as shown by CTX levels and osteoclast number.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, PTH (1-34) increased trabecular thickness similarly to abaloparatide.

    In plain wordsIn mice, PTH (1-34) increased trabecular thickness similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTrabecular thickness
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    With both PTH (1-34) and abaloparatide, μCT and histomorphometry analyses revealed similar increases in bone volume associated with an increased trabecular thickness, in bone formation rate as shown by P1NP serum level and in vivo double labeling, and in bone resorption as shown by CTX levels and osteoclast number.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, abaloparatide increased bone formation rate, supported by serum P1NP and double labeling, similarly to PTH (1-34).

    In plain wordsIn mice, abaloparatide increased bone formation similarly to PTH (1-34).

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBone formation rate
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    With both PTH (1-34) and abaloparatide, μCT and histomorphometry analyses revealed similar increases in bone volume associated with an increased trabecular thickness, in bone formation rate as shown by P1NP serum level and in vivo double labeling, and in bone resorption as shown by CTX levels and osteoclast number.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, PTH (1-34) increased bone formation rate, supported by serum P1NP and double labeling, similarly to abaloparatide.

    In plain wordsIn mice, PTH (1-34) increased bone formation similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBone formation rate
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    With both PTH (1-34) and abaloparatide, μCT and histomorphometry analyses revealed similar increases in bone volume associated with an increased trabecular thickness, in bone formation rate as shown by P1NP serum level and in vivo double labeling, and in bone resorption as shown by CTX levels and osteoclast number.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, abaloparatide increased bone resorption, supported by CTX and osteoclast number, similarly to PTH (1-34).

    In plain wordsIn mice, abaloparatide increased bone resorption similarly to PTH (1-34).

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBone resorption
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    With both PTH (1-34) and abaloparatide, μCT and histomorphometry analyses revealed similar increases in bone volume associated with an increased trabecular thickness, in bone formation rate as shown by P1NP serum level and in vivo double labeling, and in bone resorption as shown by CTX levels and osteoclast number.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, PTH (1-34) increased bone resorption, supported by CTX and osteoclast number, similarly to abaloparatide.

    In plain wordsIn mice, PTH (1-34) increased bone resorption similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBone resorption
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    With both PTH (1-34) and abaloparatide, μCT and histomorphometry analyses revealed similar increases in bone volume associated with an increased trabecular thickness, in bone formation rate as shown by P1NP serum level and in vivo double labeling, and in bone resorption as shown by CTX levels and osteoclast number.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, abaloparatide increased serum P1NP as evidence of increased bone formation, similarly to PTH (1-34).

    In plain wordsIn mice, abaloparatide increased the bone formation marker P1NP similarly to PTH (1-34).

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeSerum P1NP
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    With both PTH (1-34) and abaloparatide, μCT and histomorphometry analyses revealed similar increases in bone volume associated with an increased trabecular thickness, in bone formation rate as shown by P1NP serum level and in vivo double labeling, and in bone resorption as shown by CTX levels and osteoclast number.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, PTH (1-34) increased serum P1NP as evidence of increased bone formation, similarly to abaloparatide.

    In plain wordsIn mice, PTH (1-34) increased the bone formation marker P1NP similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeSerum P1NP
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    With both PTH (1-34) and abaloparatide, μCT and histomorphometry analyses revealed similar increases in bone volume associated with an increased trabecular thickness, in bone formation rate as shown by P1NP serum level and in vivo double labeling, and in bone resorption as shown by CTX levels and osteoclast number.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, abaloparatide increased CTX as evidence of increased bone resorption, similarly to PTH (1-34).

    In plain wordsIn mice, abaloparatide increased the bone resorption marker CTX similarly to PTH (1-34).

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeSerum CTX
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    With both PTH (1-34) and abaloparatide, μCT and histomorphometry analyses revealed similar increases in bone volume associated with an increased trabecular thickness, in bone formation rate as shown by P1NP serum level and in vivo double labeling, and in bone resorption as shown by CTX levels and osteoclast number.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, PTH (1-34) increased CTX as evidence of increased bone resorption, similarly to abaloparatide.

    In plain wordsIn mice, PTH (1-34) increased the bone resorption marker CTX similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeSerum CTX
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    With both PTH (1-34) and abaloparatide, μCT and histomorphometry analyses revealed similar increases in bone volume associated with an increased trabecular thickness, in bone formation rate as shown by P1NP serum level and in vivo double labeling, and in bone resorption as shown by CTX levels and osteoclast number.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, abaloparatide increased osteoclast number similarly to PTH (1-34).

    In plain wordsIn mice, abaloparatide increased bone-resorbing cell numbers similarly to PTH (1-34).

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeOsteoclast number
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    With both PTH (1-34) and abaloparatide, μCT and histomorphometry analyses revealed similar increases in bone volume associated with an increased trabecular thickness, in bone formation rate as shown by P1NP serum level and in vivo double labeling, and in bone resorption as shown by CTX levels and osteoclast number.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  16. 16AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, PTH (1-34) increased osteoclast number similarly to abaloparatide.

    In plain wordsIn mice, PTH (1-34) increased bone-resorbing cell numbers similarly to abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeOsteoclast number
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    With both PTH (1-34) and abaloparatide, μCT and histomorphometry analyses revealed similar increases in bone volume associated with an increased trabecular thickness, in bone formation rate as shown by P1NP serum level and in vivo double labeling, and in bone resorption as shown by CTX levels and osteoclast number.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  17. 17AnimalAnimal study (in vivo)Mechanism

    In male mice, abaloparatide increased Runx2, Col1A1, Alpl, Bsp, Ocn, Sost, Rankl/Opg, and c-fos expression at different time points.

    In plain wordsIn mice, abaloparatide increased several bone-related genes at different times.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    IncreaseOsteoblastic gene expression
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Gene expression analyses of trabecular and cortical bone showed that PTH (1-34) and abaloparatide led to different actions in osteoblast differentiation and activity, with increased Runx2, Col1A1, Alpl, Bsp, Ocn, Sost, Rankl/Opg, and c-fos at different time points.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  18. 18AnimalAnimal study (in vivo)Mechanism

    In male mice, PTH (1-34) increased Runx2, Col1A1, Alpl, Bsp, Ocn, Sost, Rankl/Opg, and c-fos expression at different time points.

    In plain wordsIn mice, PTH (1-34) increased several bone-related genes at different times.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseOsteoblastic gene expression
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Gene expression analyses of trabecular and cortical bone showed that PTH (1-34) and abaloparatide led to different actions in osteoblast differentiation and activity, with increased Runx2, Col1A1, Alpl, Bsp, Ocn, Sost, Rankl/Opg, and c-fos at different time points.
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  19. 19AnimalAnimal study (in vivo)Mechanism

    In male mice, abaloparatide appeared to produce a faster osteoblastic gene expression response than PTH (1-34).

    In plain wordsIn mice, abaloparatide appeared to change bone-forming cell gene expression faster than PTH (1-34).

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    MixedOsteoblastic gene response timing
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    PTH (1-34)
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Abaloparatide seems to generate a faster response on osteoblastic gene expression than PTH (1-34).
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.
  20. 20AnimalAnimal study (in vivo)Mechanism

    In male mice, PTH (1-34) appeared to produce a slower osteoblastic gene expression response than abaloparatide.

    In plain wordsIn mice, PTH (1-34) appeared to change bone-forming cell gene expression slower than abaloparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    MixedOsteoblastic gene response timing
    Study

    mousen: not reported in source

    male C57Bl/6J mice
    Comparator
    abaloparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 μg/kg/d · subcutaneous · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Abaloparatide seems to generate a faster response on osteoblastic gene expression than PTH (1-34).
    2 context sentences
    Summary · context
    This study aims to compare the effects of PTH (1-34), PTHrP (1-36), and abaloparatide on bone remodeling in male mice.
    Summary · context
    Intermittent daily subcutaneous injections of 80 μg/kg/d were administered to 4-month-old C57Bl/6J male mice for 6 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.